Monograph

The Ministry of Health’s Drug Advisory Committee has not recommended talquetamab for inclusion on the MOH List of Subsidised Drugs for treating relapsed or refractory multiple myeloma in patients who have received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent, and an anti-cluster of differentiation 38 antibody, and have demonstrated disease progression on the last therapy. The decision was based on the uncertainty surrounding the extent of talquetamab’s comparative effectiveness, unacceptable cost effectiveness compared with physician’s choice of treatment, and the unacceptable price-volume agreement proposed by the company.

Clinical indication, subsidy class and MediShield Life claim limit for talquetamab are provided in the Annex.